SANOFI-ADR (SNY)
US80105N1054 - ADR
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 193 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. SNY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. SNY also has an excellent dividend rating. These ratings would make SNY suitable for value and dividend investing!
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
In the past year SNY had a positive cash flow from operations.
Each year in the past 5 years SNY has been profitable.
In the past 5 years SNY always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.07%, SNY belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
SNY has a Return On Equity of 10.83%. This is amongst the best in the industry. SNY outperforms 89.01% of its industry peers.
SNY's Return On Invested Capital of 12.36% is amongst the best of the industry. SNY outperforms 90.58% of its industry peers.
SNY had an Average Return On Invested Capital over the past 3 years of 7.23%. This is significantly below the industry average of 43.18%.
The 3 year average ROIC (7.23%) for SNY is below the current ROIC(12.36%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROIC | 12.36% |
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.23%
ROIC(5y)6.72%
1.3 Margins
The Profit Margin of SNY (11.06%) is better than 86.91% of its industry peers.
SNY's Profit Margin has been stable in the last couple of years.
SNY has a better Operating Margin (21.92%) than 87.96% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 69.08%, SNY is in the better half of the industry, outperforming 72.25% of the companies in the same industry.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% |
OM growth 3Y0.85%
OM growth 5Y2.94%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, SNY has about the same amount of shares outstanding.
The number of shares outstanding for SNY has been increased compared to 5 years ago.
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.86 indicates that SNY is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.86, SNY is doing good in the industry, outperforming 73.82% of the companies in the same industry.
The Debt to FCF ratio of SNY is 5.74, which is a neutral value as it means it would take SNY, 5.74 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of SNY (5.74) is better than 85.86% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that SNY is not too dependend on debt financing.
SNY's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. SNY outperforms 43.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 2.86 |
ROIC/WACC1.74
WACC7.09%
2.3 Liquidity
SNY has a Current Ratio of 1.00. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.00, SNY is doing worse than 84.82% of the companies in the same industry.
SNY has a Quick Ratio of 1.00. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.65, SNY is doing worse than 91.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -1.61% in the last year.
Measured over the past years, SNY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.19% on average per year.
The Revenue has been growing slightly by 4.26% in the past year.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.42% yearly.
EPS 1Y (TTM)-1.61%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%12.14%
Revenue 1Y (TTM)4.26%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%12.32%
3.2 Future
The Earnings Per Share is expected to grow by 6.56% on average over the next years.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 5.21% on average per year.
EPS Next Y-4.9%
EPS Next 2Y3.64%
EPS Next 3Y5.55%
EPS Next 5Y6.56%
Revenue Next Year5.19%
Revenue Next 2Y5.93%
Revenue Next 3Y5.96%
Revenue Next 5Y5.21%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.44 indicates a reasonable valuation of SNY.
Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 90.58% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.73, SNY is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 10.55, the valuation of SNY can be described as reasonable.
Based on the Price/Forward Earnings ratio, SNY is valued cheaply inside the industry as 86.39% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (22.83), we can say SNY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.44 | ||
| Fwd PE | 10.55 |
4.2 Price Multiples
SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 93.72% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNY is valued cheaper than 82.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.82 | ||
| EV/EBITDA | 6.59 |
4.3 Compensation for Growth
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.4
EPS Next 2Y3.64%
EPS Next 3Y5.55%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.11%, SNY is a good candidate for dividend investing.
SNY's Dividend Yield is rather good when compared to the industry average which is at 4.42. SNY pays more dividend than 95.81% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.34, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.11% |
5.2 History
The dividend of SNY has a limited annual growth rate of 3.34%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased recently.
Dividend Growth(5Y)3.34%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
59.74% of the earnings are spent on dividend by SNY. This is a bit on the high side, but may be sustainable.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP59.74%
EPS Next 2Y3.64%
EPS Next 3Y5.55%
SANOFI-ADR
NASDAQ:SNY (12/20/2024, 8:00:02 PM)
After market: 47.71 0 (0%)47.71
+0.21 (+0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.52%
Inst Owner Change5.34%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap119.62B
Analysts79.29
Price Target60.43 (26.66%)
Short Float %0.41%
Short Ratio1.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.11% |
Dividend Growth(5Y)3.34%
DP59.74%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.02%
Min EPS beat(2)2.32%
Max EPS beat(2)3.72%
EPS beat(4)2
Avg EPS beat(4)0.32%
Min EPS beat(4)-2.41%
Max EPS beat(4)3.72%
EPS beat(8)5
Avg EPS beat(8)2.05%
EPS beat(12)9
Avg EPS beat(12)3.25%
EPS beat(16)13
Avg EPS beat(16)3.91%
Revenue beat(2)1
Avg Revenue beat(2)0.68%
Min Revenue beat(2)-0.35%
Max Revenue beat(2)1.71%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)1.71%
Revenue beat(8)3
Avg Revenue beat(8)14.24%
Revenue beat(12)7
Avg Revenue beat(12)28.34%
Revenue beat(16)11
Avg Revenue beat(16)34.58%
PT rev (1m)-3.5%
PT rev (3m)-2.74%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)-1.48%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.44 | ||
| Fwd PE | 10.55 | ||
| P/S | 1.62 | ||
| P/FCF | 27.82 | ||
| P/OCF | 14.18 | ||
| P/B | 1.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.59 |
EPS(TTM)4.17
EY8.74%
EPS(NY)4.52
Fwd EY9.48%
FCF(TTM)1.71
FCFY3.59%
OCF(TTM)3.36
OCFY7.05%
SpS29.51
BVpS30.12
TBVpS-1.68
PEG (NY)N/A
PEG (5Y)1.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROCE | 15.65% | ||
| ROIC | 12.36% | ||
| ROICexc | 13.27% | ||
| ROICexgc | 75.28% | ||
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% | ||
| FCFM | 5.81% |
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.23%
ROIC(5y)6.72%
ROICexc(3y)8.13%
ROICexc(5y)7.63%
ROICexgc(3y)39.23%
ROICexgc(5y)35.01%
ROCE(3y)9.15%
ROCE(5y)8.51%
ROICexcg growth 3Y4.96%
ROICexcg growth 5Y9.87%
ROICexc growth 3Y3.21%
ROICexc growth 5Y7.01%
OM growth 3Y0.85%
OM growth 5Y2.94%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%
F-Score5
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 5.74 | ||
| Debt/EBITDA | 0.72 | ||
| Cap/Depr | 90.48% | ||
| Cap/Sales | 5.59% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 40.58% | ||
| Profit Quality | 52.55% | ||
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z | 2.86 |
F-Score5
WACC7.09%
ROIC/WACC1.74
Cap/Depr(3y)62.81%
Cap/Depr(5y)53.83%
Cap/Sales(3y)5.53%
Cap/Sales(5y)5.38%
Profit Quality(3y)123.22%
Profit Quality(5y)125.66%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.61%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%12.14%
EPS Next Y-4.9%
EPS Next 2Y3.64%
EPS Next 3Y5.55%
EPS Next 5Y6.56%
Revenue 1Y (TTM)4.26%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%12.32%
Revenue Next Year5.19%
Revenue Next 2Y5.93%
Revenue Next 3Y5.96%
Revenue Next 5Y5.21%
EBIT growth 1Y-19.82%
EBIT growth 3Y8.43%
EBIT growth 5Y8.52%
EBIT Next Year16.18%
EBIT Next 3Y11.74%
EBIT Next 5Y8.81%
FCF growth 1Y-45.51%
FCF growth 3Y10.68%
FCF growth 5Y15.17%
OCF growth 1Y-15.61%
OCF growth 3Y11.41%
OCF growth 5Y13.08%